Pharnext: Successful Intermediate Analyses for PLEO-CMT Phase III Clinical Trial in Charcot-Marie-Tooth Disease Type 1A
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach for the development of innovative drugs based on the combination and repositioning of known drugs, today announced successful intermediate analyses for its Phase III clinical trial, PLEO-CMT, in Charcot-Marie-Tooth Disease Type 1A (CMT1A).
PLEO-CMT is a pivotal, multi-center, randomized, 15 months, double blind, placebo-controlled Phase III study that was initiated in December 2015 and has enrolled 323 patients with mild-to-moderate CMT1A in 30 sites across Europe, the U.S. and Canada. As the study will be completed at the end of 2018, two intermediate analyses, a blind variability analysis followed by a futility analysis, were therefore carried out as planned.
According to Professor Philippe Lehert, member of the Independent Data Safety Monitoring Board (DSMB), the variability of tests between patients is indeed within predefined limits. In addition, the futility analysis concludes that PLEO-CMT is sufficiently powered to detect an effect of PXT3003 on the primary efficacy endpoint. These two analyses follow two favorable intermediate safety analyses delivered by the DSMB in November 2016 and September 2017 and indicate therefore that PLEO-CMT can continue according to the original plan without having to increase the trial size.
Pr. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext said « These two analyses are additional steps successfully reached for the PLEO-CMT study. They allow us to confirm the schedule for final results by the second half of 2018. »
About the Data Safety Monitoring Board (DSMB)
The DSMB is an
independent body of experts drawn from the fields of clinical medicine,
biostatistics and study methodology, chartered to provide
recommendations to Pharnext upon regular pre-specified review of the
accumulated data during the conduct of the clinical trial.
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase III trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer
of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies
and develops synergic combinations of repositioned drugs at new optimal
lower doses. These PLEODRUG™ offer several key advantages: efficacy,
safety and intellectual property including several product or
composition of matter patents already granted. The Company is supported
by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
code: FR0011191287).
For more information, visit www.pharnext.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171129005955/en/
Contact information
Pharnext
René GoedKoop
Chief Medical Officer
medical@pharnext.com
+33
(0)1 41 09 22 30
or
Investor Relations (Europe)
MC
Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49
211 529252 22
or
Investor Relations (U.S.)
Stern
Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1
212 362 1200
or
Financial Communication (France)
Actifin
Stéphane
Ruiz
sruiz@actifin.fr
+33
(0)1 56 88 11 15
or
Media Relations (Europe)
ALIZE
RP
Caroline Carmagnol
Aurore Gangloff
pharnext@alizerp.com
+33
(0)1 44 54 36 64
or
Media Relations (U.S.)
RooneyPartners
Marion
Janic
mjanic@rooneyco.com
+1
212 223 4017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect29.5.2025 09:13:00 EEST | Press release
Revolutionary Platform Sets New Benchmark for Transparency and Compliance in Diagnostic AI As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry’s first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning. The technology is backed by over 15 years of experience and millions of successfully processed samples with >99.9% proven accuracy. The CE-IVDR Strategic Advantage Platform is Diagnostics.ai's response to the new wave of stringent EU regulations under the In Vitro Diagnostic Medical Devices Regulation (IVDR), which demand heightened standards for diagnostic accuracy, reproducibility, and algorithm transparency. “While most diagnostic algorithms remain an impenetrable ‘black box,’ the PCR.AI API was engineered with transparency included from the ground up,” said Aron Cohen, Chief Executive Officer of Diagnosti
From Ancient Grounds to an Intelligent Future: The 1st International Humanoid Olympiad Launches in Olympia, Greece29.5.2025 01:47:00 EEST | Press release
This year, Olympia, Greece, the birthplace of the Olympic Games, welcomes the inaugural International Humanoid Olympiad. From August 29th to September 2nd, at the International Olympic Academy in Olympia, humanoid robots will participate in demonstrations and Olympic-inspired games, showcasing their dexterity and intelligence, while global leaders in robotics and AI will share insights through expert talks and workshops. Blending millennia-old values, ethos, and ideals with a bold vision for the future, the event will spotlight how human creativity and robotics are shaping the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528788233/en/ This global gathering brings together state-of-the-art humanoid robots in spectacular showcases designed to captivate audiences of all ages and backgrounds while their creators, researchers, engineers, students, and visionaries are pushing the boundaries of what intelligent machine
Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair28.5.2025 23:29:00 EEST | Press release
Mary Kay Inc., a global advocate for furthering young women’s education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainable packaging innovation and protecting our planet’s most valuable resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528325390/en/ Kristin Dasaro, Director, Package Engineering and Sustainability at Mary Kay, greets Brazilian cancer researcher, Carolina de Araujo Pereira da Silva, who received back-to-back awards from Mary Kay for innovative findings in the malignancy of tumors. (Photo Credit: Mary Kay Inc.) Each year, the event convenes nearly 2,000
Duravant Completes Acquisition of Pattyn28.5.2025 20:44:00 EEST | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the protein processing, food sorting and handling, packaging, and material handling sectors, announced the completion of its acquisition of the Pattyn Group BV (“Pattyn”), a leading manufacturer of packaging automation systems headquartered in Bruges, Belgium. The transaction was first announced on February 7, 2025, and was completed today. With over 70 years of expertise, Pattyn is a trusted partner for companies looking to automate bulk packaging operations in industries ranging from food and ingredients to non-food applications. Pattyn has been a world-renowned brand specializing in bag-in-box packaging technology, and their comprehensive end-of-line solutions span the entire packaging process from case erecting and bag inserting to weigh filling, bag and case closing, and palletizing. “We are extremely excited to welcome Pattyn to the Duravant family,” said Mike Kachmer, Chairman and CEO o
Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer28.5.2025 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Vijay Kumar as executive vice president (EVP) and chief operating officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528704180/en/ Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer In this role, Mr. Kumar leads product management, service strategy and offerings for Rimini Street’s “Support, Optimize and Innovate” solutions and oversees Rimini Street’s Global Capability Centers (GCC). Mr. Kumar also drives operational efficiency and innovation of the portfolio to increase profitability and accelerate top line revenue growth. New COO Brings Broad Operational Experience and Capabilities Kumar is a seasoned technology executive with more than 25 yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom